Food & Drug Administration’s (FDA) Open Public Hearing

Emily and Alex were among 42 parents who travelled to the US in April 2016, to witness the Adcomm for Eteplirsen, an exon skipping drug being developed by Sarepta Therapeutics. Read more about this in our news section.

Published on 12 December 2016

Share this article
Categories Uncategorised